Quarterly report pursuant to Section 13 or 15(d)

Stock Warrants

Stock Warrants

9 Months Ended

Sep. 30, 2022

10. Stock Warrants

As of September 30, 2022 and December 31, 2021, the Company had warrants to purchase the underlying common stock outstanding as shown in the table below.


	September 30, 2022		December 31, 2021
2020 Warrants		8,819,904		8,819,904
2017 Warrants		—		1,599,645
Pfizer Warrant		505,617		505,617
Other warrants (1)		—		1,428

Warrants to purchase common stock		9,325,521		10,926,594

Weighted-average exercise price per share	$	4.90	$	6.47

(1)	Other warrants are comprised of warrants issued prior to the Company’s initial public offering (“IPO”), generally in exchange for services rendered to the Company.

The following table summarizes information regarding the Company’s warrants outstanding at September 30, 2022:


Exercise Prices	Shares Underlying Outstanding Warrants		Expiration Date
$4.90		9,325,521	May 27, 2023